Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
June 4, 2002
Assignee:
Curis, Inc.
Inventors:
Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
Abstract: Disclosed are novel compositions of morphogenic proteins constituting soluble forms of these proteins, antibodies that distinguish between soluble and mature forms, and method for producing these morphogenic proteins and antibodies.
Type:
Grant
Filed:
March 13, 1995
Date of Patent:
May 28, 2002
Assignee:
Curis, Inc.
Inventors:
William K. Jones, Ronald F. Tucker, David C. Rueger, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath
Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.
Type:
Grant
Filed:
October 13, 1998
Date of Patent:
December 25, 2001
Assignee:
Curis, Inc.
Inventors:
Thangavel Kuberasampath, Charles M. Cohen, Herrmann Oppermann, Engin Ozkaynak, David C. Rueger, John E. Smart, Roy H. L. Pang
Abstract: The present invention relates to a substantially pure population of viable pancreatic progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.
Abstract: The present invention relates to the discovery of a new member of the hedgehog receptor family, referred to herein as human ptc-2 (for patched-2 protein). The human ptc-2 polypeptides of the present invention include polypeptides which bind the products of the hedgehog gene family. Hedgehog family members are known for their broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, both adult and embryonic, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.
Abstract: The present invention is a method for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The method is particularly adapted to alleviating the tissue destructive effects associated with ischemia-reperfusion injury and hyperoxia injury.
Type:
Grant
Filed:
May 15, 1995
Date of Patent:
September 11, 2001
Assignee:
Curis, Inc.
Inventors:
Thangavel Kuberasampath, Roy H. L. Pang, Herrmann Oppermann, David C. Rueger, Charles M. Cohen
Abstract: Disclosed are methods of utilizing a morphogenically active fragment of 60A protein to induce tissue morphogenesis, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.
Type:
Grant
Filed:
July 7, 1994
Date of Patent:
April 3, 2001
Assignee:
Curis, Inc.
Inventors:
Thangavel Kuberasampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger, Charles M. Cohen
Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic VH and VL dimers, 2) VH-VL or VL-VH single chains wherein the VH and VL are attached by a polypeptide linker, or 3) individual VH or VL domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The proteins may also include other polypeptide sequences which function e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the proteins, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.